Search

Your search keyword '"Statland, Jeffrey"' showing total 335 results

Search Constraints

Start Over You searched for: Author "Statland, Jeffrey" Remove constraint Author: "Statland, Jeffrey" Language english Remove constraint Language: english
335 results on '"Statland, Jeffrey"'

Search Results

1. Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A

3. Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis

4. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

5. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial

6. Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial

8. Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial

9. Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial

11. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

12. Health related quality of life in young, steroid-naïve boys with Duchenne muscular dystrophy

13. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

14. Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

16. Outcomes after intervention for enteral nutrition in patients with amyotrophic lateral sclerosis in multidisciplinary clinics.

18. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A

20. Regional and bilateral MRI and gene signatures in facioscapulohumeral dystrophy: implications for clinical trial design and mechanisms of disease progression.

23. Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis

25. Longitudinal course of neurofilament light chain levels in amyotrophic lateral sclerosis—insights from a completed randomized controlled trial with rasagiline.

26. A longitudinal study of disease progression in facioscapulohumeral muscular dystrophy (FSHD).

27. Autosomal dominant in cis D4Z4 repeat array duplication alleles in facioscapulohumeral dystrophy.

31. Early onset as a marker for disease severity in FSHD

33. Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study

34. List of Contributors

35. Consensus-based care recommendations for adults with myotonic dystrophy type 1

37. The amyotrophic lateral sclerosis-health index (ALS-HI): development and evaluation of a novel outcome measure.

41. Phase 2 trial in acetylcholine receptor antibody‐positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg study.

42. The Changing Health and Social Circumstances of Women Leaving Jails: A Three-Year Longitudinal Study

44. Demographics, Clinical Characteristics, and Prognostic Factors of ALS in Midwest

47. Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis

48. Self-reported reduced sleep quality and excessive daytime sleepiness in facioscapulohumeral muscular dystrophy.

Catalog

Books, media, physical & digital resources